Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides.
Lipofectin, which is a mixture of neutral lipid with a cationic lipid, has been widely used to enhance cellular delivery of phosphorothioate, 2'-sugar-modified, and chimeric antisense oligonucleotides. Phosphodiester oligonucleotides delivered with Lipofectin usually do not elicit antisense activity probably because cationic lipid formulations do not sufficiently protect unmodified oligonucleotides from nuclease degradation. We show that a cationic polymer, polyethylenimine (PEI), improves the uptake and antisense activity of 3'-capped 20-mer and 12-mer antisense phosphodiester oligonucleotides (PO-ODN) targeted to different regions of Ha-ras mRNA and to the 3'-untranslated region (3'-UTR) of C-raf kinase. In contrast, PEI, which forms a very stable complex with the 20-mer phosphorothioate oligonucleotide (PS-ODN), does not enhance its antisense activity. Using fluorescently labeled carriers and ODN, we show that PEI-PS-ODN particles are very efficiently taken up by cells but PS-ODN is not dissociated from the carrier. Our results indicate that carrier-ODN particle size and stability and ODN release kinetics vary with the chemical nature of the ODN and the carrier being transfected into the cells. The very low cost of PEI compared with cytofectins and the increased affinity for target mRNA and decreased affinity for proteins of PO-ODN compared with PS-ODN make the use of PEI-PO-ODN very attractive.
Dheur
S
S
Laboratoire de Biophysique, Muséum National d'Histoire Naturelle, Paris, France.
Dias
N
N
van Aerschot
A
A
Herdewijn
P
P
Bettinger
T
T
Rémy
J S
JS
Hélène
C
C
Saison-Behmoaras
E T
ET
D001483:Base Sequence; D004337:Drug Carriers; D015870:Gene Expression; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000235:genetics; D010316:Particle Size; D010714:Phosphatidylethanolamines / Q000008:administration & dosage*; D011094:Polyethyleneimine / Q000008:administration & dosage*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013873:Thionucleotides / Q000008:administration & dosage / Q000235:genetics; D014407:Tumor Cells, Cultured
D004337:Drug Carriers; D016376:Oligonucleotides, Antisense; D010714:Phosphatidylethanolamines; D012333:RNA, Messenger; D013873:Thionucleotides; C020888:1,2-dielaidoylphosphatidylethanolamine; D011094:Polyethyleneimine